VIATRIS INC. Research and Development in Process
VIATRIS INC. (VTRS) reported Research and Development in Process of $36.40 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-02-27
- VIATRIS INC. research and development in process for fiscal 2022 was $36.40M, a 48.07% decline from fiscal 2021.
- VIATRIS INC. research and development in process for fiscal 2021 was $70.10M, a 64.94% increase from fiscal 2020.
- VIATRIS INC. research and development in process for fiscal 2020 was $42.50M.
| Period end | Research and Development in Process 12 month |
|---|---|
| 2022-12-31 | $36.40M 10-K · filed 2023-02-27 |
| 2021-12-31 | $70.10M 10-K · filed 2023-02-27 |
| 2020-12-31 | $42.50M 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |